Trump's Stock Picks Perfectly Timed With New Medicare Rules: Report

Donald Trump disclosed up to $680,000 in Eli Lilly stock purchases as Medicare initiatives advanced GLP-1 drug coverage.

Supreme Court Hands Major Blow To Big Pharma's Fight Against Biden-Era Medicare Drug Pricing Law

Supreme Court lets Medicare drug price negotiations continue, rejecting pharma industry challenges to the Biden-era program.

Supreme Court Rejects Eli Lilly Appeal In Medicaid Fraud Case

Supreme Court lets stand $194 million Medicaid fraud award against Eli Lilly in whistleblower case challenging False Claims Act.

UPDATED: 'The U.S. Supreme Court Let Stand A $194M Award Against Eli Lilly & Co. In A Whistleblower Suit Accusing The Company Of Engaging In Medicaid Fraud By Misreporting Its Drug Pr

https://www.bloomberg.com/news/articles/2026-05-18/lilly-rebuffed-by-supreme-court-on-194-million-medicaid-award

If You Invested $1000 In Eli Lilly Stock 20 Years Ago, You Would Have This Much Today

Dominion Energy, Apple And A Health Care Stock: CNBC's 'Final Trades'

On CNBC's Halftime Report Final Trades, Bill Baruch highlights Eli Lilly's great earnings. Dominion Energy and Apple also see positive results.

CNBC Halftime Report Final Trades: Eli Lilly, Apple, Dominion Energy

Trump's Drug Pricing Plan Gains Surprise Democratic Ally— Peter Welch Vows To 'Make It Happen'

Democrat Sen. Peter Welch backs Trump's MFN drug pricing plan as bipartisan pressure over prescription costs grows.

This Weight-Loss Drug Challenger Could Follow Eli Lilly's Playbook: Analyst

William Blair gives Kailera Therapeutics ($KLRA) an Outperform rating. Learn why analysts see a competitive edge in their GLP-1 assets.

Cathie Wood, Ross Gerber Snap Up The Same 10 Stocks — Here's The Unlikely Portfolio Crossover

Cathie Wood and Ross Gerber are both well known investors. Here's a look at the stocks they both hold across their ETFs.